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H
HIV/Hepatitis Prevention in Drug Abuse Treatment Programs: 
Guidance From Research 
A large body of research examines the relationship between HIV and drug dependence, but 
considerably less information is available on viral hepatitis and drug dependence. This article 
summarizes research indicating what drug abuse treatment programs can do to prevent 
their patients from acquiring HIV or hepatitis infection and to limit the consequences for 
patients who are already infected. Drug treatment programs can play a pivotal role in pre­
venting, detecting, and treating HIV and hepatitis. Some activities can be accomplished by 
providers’ simply becoming aware of the issues; others will require significant infusion of 
leadership, education, and fiscal support. 
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I I
n the United States, drug users have been disproportionately affected by the 
AIDS epidemic. As a result, the substance abuse research community has devel­
oped substantial knowledge about how to prevent HIV infection and systems to 
facilitate the management of those already infected. Yet, the drug treatment prac­
titioner’s current knowledge of hepatitis, particularly hepatitis C, is similar to what 
was known about AIDS a decade ago. There is a growing, but still incomplete, 
understanding of the transmission of hepatitis C, its acute presentation, and how 
it behaves as a chronic infection. Treatment is available for chronic hepatitis C. 
While treatment effectiveness may be limited, the importance of detecting hep­
atitis C infection, particularly acute (new-onset) infection, has been bolstered 
by recent evidence that treatment during the acute stage may prevent the estab­
lishment of chronic infection (Jaeckel et al., 2001). 
In drug treatment programs, addressing medical issues such as infectious dis­
eases may be secondary to the goal of reducing patients’ drug abuse. Staff mem­
bers in drug treatment programs may wonder how much attention they should 
give to these problems, particularly if they feel they have little to offer clients by 
way of prevention or treatment. Nevertheless, by decreasing drug use and HIV 
risk behaviors and by educating patients about HIV, drug abuse treatment has 
become one of the most powerful AIDS prevention techniques in our public health 
arsenal. With adequate funding and public health support, drug abuse treatment 
programs can play a central role in preventing and detecting hepatitis as well. RESEARCH REVIEWS—HIV/HEPATITIS PREVENTION • 5 
Drug abuse treatment providers have unequaled 
opportunity to reach drug abusers with health infor­
mation and interventions. This article presents a num­
ber of suggestions, based on research, about what a 
drug treatment program can do to address HIV and 
hepatitis infections. First we review the extent of these 
infections among drug users. Then we discuss tech­
niques for using research-developed assessment and 
diagnostic tools. Finally, we suggest primary and sec­
ondary preventive activities that a treatment program 
can implement to limit the spread and consequences 
of infection. 
PREVALENCE OF HIV AND HEPATITIS 
AMONG DRUG USERS 
The prevalence of HIV among drug users entering 
treatment varies across different settings, ranging from 
0 to 35 percent. Some transmission of HIV contin­
ues among those in drug abuse treatment, especially 
younger injecting drug users (IDUs) (Murrill et al., 
2001). IDUs are at high risk of infection with HIV 
and hepatitis A, B, and C viruses through unsterile 
injection practices and unsafe sexual behaviors. Injection 
drug use is a factor in one-third of all AIDS cases in 
the United States, more than one-half of new HIV 
infections, and one-half of new hepatitis C infections. 
IDUs as a group have high prevalence of viral hepa­
titis: Approximately 40 to 70 percent develop hepa­
titis A infection at some time in their injection careers, 
while their prevalence rates for hepatitis B and C 
are 50 to 90 percent. Some noninjecting users of illicit 
drugs, such as crack smokers, are also at risk of con­
tracting viral hepatitis. 
Hepatitis is an inflammation of the liver, most 
often caused by alcohol or a virus. In the past, health 
providers often assumed that nearly all drug users were 
infected with hepatitis A and B by the time they entered 
drug abuse treatment, but today significant numbers 
of drug users in the community are free of these viruses. 
Thus, many patients entering treatment could ben­
efit from vaccines to protect against hepatitis A and 
B. Although many or most IDUs become infected 
with hepatitis C during their first year of injecting, 
some patients entering treatment programs are still 
uninfected and susceptible. 
TRANSMISSION OF HIV AND HEPATITIS  
HIV is transmitted through sharing of unsterile syringes 
and through unprotected sexual activity. The virus 
may also be transmitted from mother to child during 
birth and the weeks before and after—the perinatal 
period. New data suggest that sexual transmission of 
HIV is also an important mode among IDUs: Male 
IDUs who have sex with men and female IDUs who 
trade sex for money are more likely to become HIV-
infected than IDUs who do not engage in those behav­
iors (Kral et al., 2001). 
There is significant overlap between modes of 
transmission and hence between risk factors for HIV 
and hepatitis A, B, and C. Because HIV and hepati­
tis are transmitted by many of the same routes, risk-
reduction efforts aimed at HIV transmission have also 
reduced the spread of hepatitis. However, hepatitis 
can be transmitted in more ways than HIV. Hepatitis 
A and B may be transmitted to household members 
and other close contacts who are not sexual 
partners. 
Hepatitis A is spread through unsanitary living 
conditions, inadequate personal hygiene, and direct 
or indirect anal-oral contact, including sexual behav­
iors. Transmission of the virus in feces predominates, 
but hepatitis A is also transmitted via contact with 
contaminated drug injection equipment. Use of con­
taminated water to prepare drugs and contamination 
of drugs hidden in the rectum may play a role. Hepatitis 
A causes acute, not chronic, inflammation of the liver. 
Hepatitis B virus is found in the semen, blood, 
and saliva of infected persons and is usually spread by 
contaminated syringes and unprotected sexual con­
tact.  From 1 to 10 percent of patients develop chronic 
liver inflammation, which may progress to cirrhosis 
and liver cancer. 
Hepatitis C virus is transmitted through con­
taminated blood (for example, during syringe shar­
ing) and through needle-stick injuries and unprotected 
sexual contact. In addition, recent research shows hep­
atitis C transmission associated with the sharing of 
unsterile injection equipment other than syringes 
(cookers, filtration cotton, rinse water) (NIDA, 2000). 
Hepatitis C appears to spread more rapidly among 
IDUs than does HIV, because of higher prevalence of 
hepatitis C among injection partners and a higher 
infectivity of hepatitis C once it gets into the blood­
stream (Garfein et al., 1996; Hagan and Des Jarlais, 
2000). From 10 to 60 percent of individuals infected 
with hepatitis C virus develop some form of chronic 
liver inflammation.  
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Drug abuse treatment and interventions such as 
syringe exchange and outreach, which have focused 
on reducing the use of contaminated syringes, have 
been associated with lower incidence of HIV infec­
tion but have had less consistent or no effects on new 
cases of hepatitis C. To affect the transmission of hep­
atitis C, risk-reduction interventions are needed 
that address not only syringe use, but also sexual behav­
iors and the use of injection paraphernalia in addition 
to syringes (such as filtration cottons, cookers, and 
rinse water). 
STAFF ASSESSING PATIENTS’ RISKS 
Tools Available 
Drug abuse treatment programs can incorporate 
risk assessment and educational messages about HIV 
risks into their intake and counseling protocols. The 
assessment must be done with an instrument that can 
reliably measure both drug-related and sex-related risk 
behaviors. Several self-report measures have been 
designed to assess drug use, injection practices, and 
sexual behaviors associated with HIV risk. Among the 
most widely used  instruments are three that have 
demonstrated high reliability and validity: the Risk 
Behavior Assessment Questionnaire (NIDA, 1991), 
the Risk Assessment Battery (Treatment Research 
Institute, www.tresearch.org/Assessment%20Inst 
/Assess_inst.html), and the Texas Christian University 
(TCU) AIDS Risk Assessment (Camacho et al., 1997; 
www.ibr.tcu.edu). 
The Risk Assessment Battery Questionnaire and 
TCU AIDS Risk Assessment may be particularly use­
ful in clinical settings because they can be adminis­
tered in 15 minutes or less and require minimal staff 
training. A computerized version of the Risk Assessment 
Battery is as accurate as the paper-and-pencil ver­
sion (Navaline et al., 1994). To maximize the accu­
racy of assessments, counselors can establish a non-
judgmental context; explicitly assure patients of privacy 
and confidentiality; explain why questions are being 
asked (when the purpose of questions is not obvious 
to a patient); consider the impact of related problems 
(such as psychiatric or legal difficulties) on assessment 
of risk behaviors; and, where appropriate and feasi­
ble, use self-administered or computerized tests to 
eliminate the need for patients to report socially 
sensitive information face to face. 
Laboratory Testing and Counseling 
Given the demonstrated clinical value of medical and 
psychosocial interventions to treat and prevent HIV, 
drug abuse treatment programs should offer HIV test­
ing and counseling. The only exceptions would be 
programs that see patients for shorter periods than the 
time needed to obtain test results and provide feed­
back. In general, IDUs who know they are infected 
engage in high-risk activities less frequently than those 
who are not infected or do not know their HIV sta­
tus. While patients newly diagnosed with HIV occa­
sionally develop stress reactions and inject drugs more 
frequently, such responses are generally transient and 
not usually associated with the increases in risky injec­
tion behaviors that can lead to further HIV trans­
mission. Supportive pretest and post-test counseling, 
which can anticipate such reactions and reduce their 
impact, are an indispensable part of the testing process. 
The rates of false positive reactions among HIV 
tests (which routinely include both ELISA and Western 
Blot assays) are extremely low; hence, any confirmed 
positive test should be taken as evidence of HIV infec­
tion. In the rare circumstances in which HIV Western 
Blot results are indeterminate, individuals should be 
referred for expert evaluation. 
Blood tests can indicate whether a patient is sus­
ceptible to hepatitis A or B (and thus should receive 
vaccine) or has antibodies that reflect previous expo­
sure and immunity (in which case vaccination is not 
needed). The tests can also reveal whether a patient has 
active or resolved hepatitis B infection. For the hepa­
titis C virus, an antibody test reveals only prior expo­
sure to the virus and does not indicate whether the 
infection is new (acute), chronic (long-term), or resolved. 
Findings indicating chronic active hepatitis B infec­
tion or evidence of exposure to hepatitis C infection 
should prompt referral for clinical evaluation and pos­
sible treatment. Screening for hepatitis B has been rec­
ommended as a routine part of care in drug abuse treat­
ment programs (Center for Substance Abuse Treatment, 
1995; www.health.org/govpubs/bkd131/), and these pro­
grams are valuable settings for hepatitis A and C screen­
ing, as well. For more specific guidance in the inter­
pretation of hepatitis tests, see box,“How To Interpret 
Hepatitis Test Results,” page 7.  
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PRIMARY PREVENTION OF INFECTION 
We use “primary prevention” to describe strategies to 
limit the drug abuse patient’s exposure to infectious 
agents and to minimize the impact of such expo­
sure. Primary prevention efforts include education 
and counseling, vaccination, and outreach to bring 
IDUs into treatment. 
Risk Education 
To address the problem of HIV/AIDS among patients 
and their contacts, drug abuse treatment programs 
have incorporated education about reducing risky 
behavior as part of drug counseling protocols. Gibson 
and colleagues (1998; also http://hivinsite.ucsf.edu/ 
InSite.jsp?page-kb-07&doc=kb-07-04-01-01) reviewed 
the controlled research evaluations of a range of coun­
seling interventions aimed at preventing IDUs from 
acquiring HIV/AIDS. They found that more inten­
sive interventions—that is, those with more patient 
contact—seemed to reduce risky injection drug use 
practices and sexual behaviors more than did less inten­
sive interventions. Components of successful programs 
include individual or group counseling sessions focused 
on skill-building, relapse prevention, and HIV coun­
seling and testing. 
Drug abuse treatment programs and syringe 
exchange programs (SEPs) can improve, however, at 
providing hepatitis prevention education and inter­
ventions. In a recent survey at two New York City 
SEPs, the majority of IDUs had previously been in 
drug abuse treatment. Although most were concerned 
about hepatitis, most had not been tested for hepati­
tis C virus, were not aware that vaccines were avail­
able to prevent hepatitis A and B, and did not know 
that hepatitis C therapy existed (Perlman et al., 2001). 
While there is debate about the optimal approach 
to hepatitis C treatment for active drug users (Edlin 
et al., 2001), few would argue against providing edu­
cation about how to reduce risks for hepatitis as part 
of drug abuse counseling. Those entering drug abuse 
treatment should be provided with education about 
viral hepatitis and offered hepatitis testing. Counseling 
can help prevent new infection among those who are 
still susceptible and help those already infected to avoid 
transmitting the disease to others. The content of coun­
seling should reflect emerging evidence that sharing of 
cottons and cookers transmits hepatitis C, that risk-
reduction strategies applied to HIV prevention can 
also help to prevent hepatitis transmission, and that 
vaccination for hepatitis A and B may be important if 
the patient is susceptible. 
Patients with chronic hepatitis B infection or 
recent or chronic hepatitis C infection should be advised 
that treatment exists that can help prevent progres­
sion of the disease, and they should be referred for 
evaluation for therapy. Chronic hepatitis B infec­
tion or other liver disease may be treated with lamivu­
dine, which is associated with improvement in liver 
function in more than 50 percent of patients treated. 
Treatment of chronic hepatitis C infection with alpha 
interferon agents alone (either alpha interferon or 
PEG-alpha interferon) or in combination with rib­
avirin may prevent progression of, or even reverse, 
liver disease in infected patients. Overall, about 30 to 
40 percent of all patients can expect to have sustained 
There is signifi­
cant overlap 
between modes 
of transmission 
and hence 
between risk 
factors for HIV 
and hepatitis 
A, B, and C. 
How To Interpret Hepatitis Test Results 
Hepatitis B 
• The absence of any hepatitis B markers demonstrates susceptibility to 
hepatitis B; vaccination is indicated. 
• The presence of hepatitis B surface antigen demonstrates active hepati­
tis B infection, which may progress to chronic liver disease. False posi­
tive tests are extremely uncommon. 
• The presence of hepatitis B surface antibody demonstrates immunity 
to hepatitis B, either from prior vaccination (in which case the hepatitis 
B core antibody would be negative) or from prior naturally acquired but 
resolved disease (in which case hepatitis B core antibody would be 
positive). 
• Some individuals may have isolated hepatitis B core IgG antibody reac­
tivity. This may be due to either low-level active infection (in which case 
a hepatitis B DNA test would be positive) or very remote resolved hepa­
titis B infection with loss of hepatitis B surface antibody over many 
years (the development of hepatitis B surface antibody in response to a 
dose of vaccine confirms this)or to a false positive hepatitis core anti­
body test. In the latter instance, hepatitis B vaccination is indicated. 
Hepatitis C 
• Hepatitis C antibody reactivity means that hepatitis C infection is likely. 
Referral for clinical evaluation is indicated 
to confirm active hepatitis C infection by documenting detectable 
hepatitis C virus by a viral load assay, 
to assess for liver disease with liver function tests, and 
possibly, to conduct a liver biopsy to consider treatment of 

hepatitis C.
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What a Drug Treatment Program Can Do To   Incorporate 
HIV/Hepatitis Prevention 
Assessment and Diagnosis 
Assess risks of acquiring or transmitting infection 
Obtain history of prior hepatitis disease and/or vaccination 
Conduct serologic screening for HIV and hepatitis 
Identify candidates for HIV treatment and for hepatitis A and B vaccines 
Preventing Infection (Primary Prevention) 
Engage patient in drug abuse treatment 
Provide pre- and post-test counseling when screening for HIV and hepatitis 
Educate and provide counseling about risky needle use and sexual risk 
behaviors 
Deliver hepatitis A and B vaccines 
Build ties to outreach agencies 
• Syringe exchange programs 
• HIV counseling and testing centers 
• Community outreach agencies 
For IDUs who continue to inject, refer to reliable sources of sterile syringes 
Limiting the Consequences of Disease (Secondary Prevention) 
Link patients to or provide primary medical care (active referral strategies, 
on-site care) 
Link patients with agencies that address their problems with retention in 
medical care and drug abuse treatment 
Promote medication adherence: reminder systems, social support, incen­
tive strategies 
General Information and Communications 
Keep abreast of changing research, ethical and legal issues 
Educate staff and community about medical complications of drug abuse 
and treatment options 
Join community leaders and patient representatives in providing informa­
tion about how to address HIV and hepatitis more effectively 
viral clearance with the combination of an interferon 
agent and ribavirin. Recent data suggest that the treat-
ment of acute hepatitis C can prevent the establish-
ment of chronic hepatitis C infection (Jaeckel et al., 
2001).
Drug treatment 
programs are in 
a pivotal posi­
tion to reach a 
population that 
is at risk for HIV 
and hepatitis 
and has high 
prevalence of 
those diseases. 
Vaccines 
Although there is not yet any vaccine against hepati­
tis C, vaccination can prevent hepatitis A and B. For 
those with chronic hepatitis C infection who are 
susceptible to hepatitis A or B, vaccination is impor­
tant, since infection with other forms of hepatitis may 
lead to liver failure. The rates of vaccination for hep­
atitis A and B are low among IDUs, however, sug­
gesting lost opportunities for prevention. The most 
successful vaccine delivery systems to date are those 
that either administer vaccines at the drug abuse treat­
ment site or use incentives to encourage patients to 
follow through on being vaccinated elsewhere. Models 
based solely on providing vouchers for free vaccines 
have produced less impressive rates of completed immu­
nization (Des Jarlais et al., 2001). 
Two vaccines for hepatitis A and two for hepa­
titis B have been approved for use in the United States. 
They should not be given to patients with prior hyper­
sensitivity to the vaccines or their components. Hepatitis 
A and hepatitis B vaccines may be used together, gen­
erally minimizing inconvenience to patients without 
increasing adverse effects or decreasing effective­
ness. Providing the two vaccines at the same time may 
also increase the likelihood that patients will complete 
the vaccine series. The hepatitis A vaccine is given at 
month 0 (the start of hepatitis treatment) and 
6 months; the hepatitis B vaccine is given at 0, 1, and 
4 to 6 months. Alternatively, for patients who need 
immunization against both hepatitis A and B, a recently 
approved combination vaccine may be used (at 0, 1, 
and 4 to 6 months) to reduce the number of injec­
tions. 
Although complete courses of each vaccine are 
needed for optimal benefit, there is significant clini­
cal value to patients who receive incomplete courses 
or even single doses; therefore, there is no need to guar­
antee that a patient will complete the series before ini­
tiating vaccination. To ensure that susceptible drug 
abusers receive at least one vaccine dose, the usual 
practice is to obtain a blood sample for testing and 
administer a first dose of vaccine at the initial visit. 
Hepatitis B vaccination in SEPs has been a 
useful component of the public health response to a 
hepatitis B outbreak among IDUs in Pierce County, 
Washington. A pilot study of SEP-based hepatitis B 
vaccination in New York City had an 83-percent rate 
of completed vaccine series (Des Jarlais et al., 2001). 
Outreach to IDUs 
Drug abuse treatment programs can build ties to other 
community-based programs for cooperative efforts in 
HIV and hepatitis prevention. Some SEPs offer HIV 
counseling and testing, flu and pneumonia vaccines, 
and other medical services either at the program site 
or by referral elsewhere. Many SEPs provide preven­
tion services in neighborhoods where drug users live 
to reach those who are unwilling or unable to use con­
ventional services elsewhere. SEPs can also promote RESEARCH REVIEWS —HIV/HEPATITIS PREVENTION • 9 
prevention by linking IDUs—including those con­
tacted through outreach efforts such as field workers’ 
visits to homes and shooting galleries—with drug 
abuse treatment. In one study, Heimer (1998) found 
that both SEP and non-SEP clients used the SEP to 
obtain referrals to drug abuse treatment, and of those 
requesting treatment, 60 percent started therapy. 
Moreover, compared with clients referred by other 
sources, drug users referred by SEPs have comparably 
good short-term drug abuse treatment outcomes. 
HIV counseling and testing centers where drug 
users present for confidential or anonymous HIV test­
ing have the potential to serve as sources of referral to 
drug abuse treatment, medical care, and other pre­
vention services. The advantage of this approach is 
that the initial contact may afford the provider an 
opportunity to engage the patient in ongoing pre­
vention and drug abuse treatment services. 
Community outreach, which relies on peers and 
community residents to identify out-of-treatment drug 
users and initiate risk-reduction counseling, may also 
serve as a conduit to prevention services. Basic risk-
reduction activities usually include raising aware­
ness about HIV and other blood-borne diseases, teach­
ing skills to reduce risky drug use and sexual behaviors, 
providing materials for protection (for example, con­
doms and bleach), and counseling and testing for HIV. 
Studies show that outreach interventions are effective 
in reducing risky injection drug use practices and 
increasing protective behaviors, including entry into 
drug abuse treatment, needle disinfection, and con­
dom use (Coyle et al., 1998). Drug treatment per­
sonnel could benefit from reading NIDA’s manual on 
how to conduct effective community outreach (NIDA, 
2000). 
In summary, linkages between drug abuse treat­
ment programs and community-based prevention serv­
ices, such as SEPs and HIV counseling and testing 
centers, have the potential to reduce the risk of both 
HIV and hepatitis. Creating formal agreements or 
linkages between drug abuse treatment programs and 
these referral sources may assist drug users in access­
ing drug abuse treatment, prevention, and health care 
services. 
SECONDARY PREVENTION: LIMITING 
DISEASE CONSEQUENCES 
The term “secondary prevention” here refers to inter­
ventions for people who are already infected with HIV 
or hepatitis. The goals of secondary prevention are to 
limit the medical consequences of infection and dimin­
ish the further spread of the disease. An excellent man­
ual for drug abuse treatment providers offers a range 
of tips and suggestions (Center for Substance Abuse 
Treatment, 2000), including ways to incorporate pri­
mary medical care, mental health, and social serv­
ices into drug abuse treatment programs; to link with 
other “wrap-around” services such as case manage­
ment; and to keep abreast of changing legal and eth­
ical issues of treating people who have HIV infection. 
Links to Primary Care 
Patients in drug abuse treatment may encounter sub­
stantial barriers to receiving health care, such as lack 
of insurance or transportation, perceived attitudes of 
providers, social disorganization, and competing pri­
orities. Patients generally receive few medical services 
while in drug abuse treatment, yet drug treatment pro­
grams can play a critical role in determining outcomes 
such as acceptance of therapy, appointment-keeping, 
and adherence to medication schedules. 
Research has provided a growing body of evi­
dence that delivering medical and psychosocial serv­
ices at drug abuse treatment sites increases patients’ 
utilization of primary medical care, medical screen­
ing, and mental health services; improves medication 
compliance and medical outcomes, retention in treat­
ment, and substance use outcomes; and reduces emer­
gency room visits (e.g., Selwyn et al., 1989). Moreover, 
HIV-related medical care programs incorporated into 
drug abuse treatment settings show high rates of uti­
lization and medication compliance and have the 
potential to deliver hepatitis prevention services to 
drug users (Selwyn et al., 1989). 
Service delivery models that provide medical care 
onsite at drug abuse treatment programs (or nearby) 
have several advantages, including attention to mul­
tiple service needs during a single visit, enhanced com­
munication between drug treatment and primary care 
providers, and the ability to accommodate patients 
who at times visit without appointments. Combining 
drug abuse treatment with regular medical care is asso­
ciated with fewer subsequent hospitalizations. Therefore, 
averting costs of inpatient stays by promoting conti­
nuity of medical and drug abuse treatment either onsite 
or through linkage mechanisms may prove to be a cost-
effective model of care for drug abusers.  
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Links to Other Services 
Relatively few studies have examined the effectiveness 
of various linkage mechanisms to promote use of med­
ical services among individuals enrolled in drug abuse 
treatment programs. Linkage strategies that have been 
used to improve drug abuse patients’ access to med­
ical care include case management and transportation. 
Findings on the utility of case management to increase 
access to medical care have been mixed, however, and 
successful case management may not be possible with­
out funding initiatives to support such programs. 
Although few studies have examined the influence of 
transportation on utilization of drug abuse treatment 
services, some evidence suggests that transportation 
may be an important linkage mechanism (Friedmann 
et al., 2000). 
Promoting Medication Adherence 
By helping patients take needed medications, drug 
abuse treatment programs can play an important role 
in the delivery of HIV/hepatitis preventive and med­
ical services. Any hepatitis vaccination program must 
consider issues of adherence, as completion of the vac­
cine series affords optimal protection. Specific data 
on factors affecting retention of IDUs in hepatitis pre­
vention programs are sparse, but a number of drug 
use, demographic, and behavioral factors have been 
associated with patients’ failure to comply with treat­
ment for drug abuse, TB, and HIV and with other 
medical interventions. Hence, programs designed 
to deliver HIV and hepatitis prevention interventions 
to IDUs in treatment settings should make use of 
strategies demonstrated or likely to promote greater 
adherence, such as positive reinforcement, incentives, 
and other strategies (see box, “What a Drug Treatment 
Program Can Do To Incorporate HIV/Hepatitis 
Prevention,” page 8). 
CONCLUSION 
Staffs in drug abuse treatment programs have con­
siderable ability to prevent, detect, and diminish the 
adverse consequences of HIV and hepatitis A, B, and 
C viruses. The boxed text summarizes the evidence-
based interventions that we recommend. Many of these 
activities (for instance, educating the staff about hep­
atitis) do not require additional resources, and some, 
such as building linkages to potential affiliate pro­
grams, make good sense for any organization. Other 
potentially valuable interventions may not be feasible 
within a treatment program’s current budget; for exam­
ple, vaccinating patients for hepatitis A and B may be 
beyond the services usually provided. Many of these 
interventions require the involvement of the com­
munity’s public health leadership. Combining drug 
abuse treatment with both hepatitis vaccination and 
interventions to reduce risk behaviors has the poten­
tial to be a highly efficient, synergistic approach to 
hepatitis prevention for IDUs and their contacts. 
Drug treatment programs are in a pivotal posi­
tion to reach a population that is at risk for HIV and 
hepatitis and has high prevalence of those diseases. 
Researchers and practitioners can be a powerful team, 
especially working with policymakers, to determine 
how drug abuse treatment programs can prevent HIV 
and hepatitis in their communities, to further dis­
seminate research-based interventions, and to bring 
many of the new HIV and hepatitis strategies into 
local treatment settings. 
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